News

In the third part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, explains why independent verification, validation, and human decision-making must stay central, as AI accelerates data processing and operational workflows across pharma supply chains.

In today’s Pharma Pulse, the FDA launches its "PreCheck" pilot to speed up domestic factory approvals, while new SELECT trial data shows that semaglutide significantly slashes hospital admission rates.

The deal strengthens Körber’s SAP supply chain and digital manufacturing consulting portfolio, extends its global footprint, and creates Körber Stellium to deliver end-to-end supply chain and software solutions.

In the second part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, notes that in order to reduce risk and accelerate adoption, supply chain leaders can begin applying AI to machine-generated data—such as IoT sensor outputs—where insights improve performance without raising concerns about data ownership, security, or competitive exposure.

In today’s Pharma Pulse, a new national survey exposes the depth of America’s prescription access crisis, while AstraZeneca and Eli Lilly commit billions of dollars to next-generation weight-loss therapies and domestic manufacturing.

This guide breaks down how AFPs function and why they are fundamentally changing the path between patients and their therapies.

In the first part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, explains how pharma leaders can detect early warning signs beyond their own silos and adapt before disruption becomes unavoidable.

In today’s Pharma Pulse, HHS issues guidance for manufacturer-direct drug discounts, while clinical data warns of significant weight regain after stopping tirzepatide and semaglutide.

For the first time, CMS has released negotiated prices for high-cost drugs covered under both Medicare Part D and Part B, naming 15 new negotiation targets and signaling continued efforts to rein in prescription drug spending.

In today’s Pharma Pulse, the AAP defies federal vaccine cuts, Morris & Dickson scales its specialty footprint, and Insilico Medicine targets cardiometabolic health with a new partnership.

In the final part of his Pharma Commerce video interview, Hari Kiran Chereddi, CEO of HRV Pharma, explains how federated intelligence, audit-ready data systems, and a culture of compliance are enabling scalable transparency across decentralized pharmaceutical manufacturing networks.

The acquisition strengthens M&D’s specialty portfolio, broadens access to plasma-derived therapies, and supports phased integration focused on regulatory compliance.

In today’s Pharma Pulse, extreme weather tests the resilience of community pharmacies, while CMS proposes a near-flat 0.09% update for Medicare Advantage and Part D payments in 2027.

The new Medicare payment model aims to take down wasteful spending, but Congress and analysts point out potential problems.

Even the threat of Greenland-related tariffs rattled drug supply chains and uncovered industry vulnerabilities to instability.

In today’s Pharma Pulse, global pharmaceutical production hits a surge as manufacturers brace for US tariff shifts, while a new study reveals how smart speakers are slashing A1C levels for older adults.

How direct-to-patient programming can transform the prescription journey for patients and manufacturers alike.

In the second part of his Pharma Commerce video interview, Hari Kiran Chereddi, CEO of HRV Pharma, describes how AI-driven orchestration, real-time data integration, and federated learning are reshaping pharmaceutical supply chains for faster, safer, and more agile operations.

In today’s Pharma Pulse, the United States finalizes its departure from global health oversight, while domestic providers face a record-breaking surge in respiratory hospitalizations.

The agency will evaluate FISP after early results show major gains in speed, capacity, and real-time risk mitigation across US ports of entry.

Artificial intelligence is helping pharma teams uncover critical safety signals faster, lower costs, and shift pharmacovigilance from compliance to competitive advantage.

In today’s Pharma Pulse, Congress races to secure funding, while Novavax nets a half-billion-dollar validation of its non-aluminum vaccine technology.

The France-based provider brings its cloud-native WMS and automation expertise to the US market.

In the final part of his Pharma Commerce video interview, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, explains how understanding premiums, coverage trade-offs, and HSAs remains a major challenge for patients—and for policymakers designing new plans.

In today’s Pharma Pulse, over 200 health groups denounce childhood vaccine schedule cuts, GSK acquires RAPT Therapeutics, and BD partners with ten23 health to scale large-volume injectors.

The partnership aims to speed commercialization, reduce risk, and enable large-volume biologics to shift from IV to subcutaneous delivery.

In the fourth part of his Pharma Commerce video interview, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, outlines the financial pressures that make sustained safety net protections a healthcare imperative.

In today’s Pharma Pulse, the FDA and EMA synchronize on AI standards, a potential divide in pricing strategy occurs, and BoomRx launches a needle-free nanoemulsion for weight loss.